NASDAQ-NMS:MIRA

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

Retrieved on: 
Thursday, March 21, 2024
Discovery, Research, Depression, Epilepsy, MIRA, Development, Shire (pharmaceutical company), Stroke, Litoxetine, IND, VPA, Sanofi, Clinical trial, Research and development, Investigational New Drug, Drug development, Marketing, Pharmaceutical industry

MIAMI, March 21, 2024 /PRNewswire/ -- MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on the development of novel treatments for neurologic and neuropsychiatric disorders, proudly announces the appointment of distinguished pharmaceutical executive Dr. Itzchak Angel as its new Chief Scientific Advisor.

Key Points: 
  • Dr. Angel brings over 40 years of preclinical, clinical and regulatory acumen to MIRA.
  • He has significantly contributed to the research, development and regulatory approval of groundbreaking medications over his remarkable career.
  • Additionally, his activities contributed to the development and marketing of Mizollen (mizolastine), Xatral (alfuzosin) and Ambien (zolpidem).
  • "We are truly honored to have Dr. Angel on our team," stated Erez Aminov, Chairman & CEO of MIRA.

MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations

Retrieved on: 
Monday, December 4, 2023
Research, Food, Deficit spending, MIRA, Disorder, THC, DSM-IV codes, Learning, FDA, Artificial intelligence, Cognition, Machine learning, Buspirone, Neuropharmacology, MD, Drug discovery, Medical cannabis, Memory, Anxiety disorder, AI, Drug development, Pharmaceutical industry, Medical device, Appetite, Anxiety

BALTIMORE, Dec. 4, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on neurologic and neuropsychiatric disorders, has released new data from artificial intelligence (AI) simulations that show that, compared to plant-based medical marijuana, there may be significant potential advantages to the therapeutic potential of MIRA1a, such as its potential to offer a superior anti-anxiety treatment, increased cognition and without the increased appetite associated with THC.

Key Points: 
  • The simulations on MIRA1a were conducted in conjunction with the Company's strategic collaboration with InSilicoTrials , a company specializing in leveraging AI and simulations to enhance drug and medical device development.
  • In silico analysis is a computational technique that uses AI to predict the interaction between drugs and their targets.
  • The simulations suggest that MIRA1a's agonistic action on the 5-HT1a receptor aligns with established anxiolytic properties in medications like Buspirone and certain SSRIs.
  • "In the groundbreaking field of neuropharmacology, artificial intelligence and machine learnings have ushered in a new era of drug discovery and analysis," said Adam Kaplin, MD, Ph.D., President and Chief Scientific Officer of MIRA Pharmaceuticals.

MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%

Retrieved on: 
Wednesday, November 29, 2023
Absorption, Caco-2, Depression, Research, Safety, Hope, MIRA, Projection, DSM-IV codes, IQVIA, Patient, Esketamine, MBBS, MD, TRD, Drug development, Drug, Suicidal ideation, Mouth, MDSI, Pharmaceutical industry, Ketamine

BALTIMORE, Nov. 29, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on neurologic diseases and neuropsychiatric disorders, today announced results from recent studies that indicate Ketamir-2's oral bioavailability is predicted to be approximately 80%.

Key Points: 
  • BALTIMORE, Nov. 29, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on neurologic diseases and neuropsychiatric disorders, today announced results from recent studies that indicate Ketamir-2's oral bioavailability is predicted to be approximately 80%.
  • Given oral Ketamine's previously determined 23% bioavailability when taken by mouth, Ketamir-2's adjusted oral bioavailability based on the CaCO-2 results is predicted to be around 80%1.
  • "This positive financial outlook bolsters our confidence in advancing Ketamir-2's clinical development," said Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals.
  • This advancement is not just a milestone for MIRA Pharmaceuticals, but a beacon of hope for millions battling severe depression."

MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a

Retrieved on: 
Tuesday, November 21, 2023
Research, Deficit spending, MIRA, THC, Learning, Mouse, Dementia, Anxiety, University, Neuropsychiatric Disease and Treatment, Grand Rounds, Neuropathic pain, Drug development, Pharmaceutical industry, Medical device, MD

BALTIMORE, Nov. 21, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company, today revealed groundbreaking insights into the cognitively enhancing effects of MIRA1a in normal mice during a presentation at the University of Louisville's Christine Lee Brown Envirome Institute's Grand Rounds from Dr. Adam Kaplin, MD, Ph.D., President and Chief Scientific Officer of MIRA Pharmaceuticals and Adjunct Faculty member at the Johns Hopkins School of Medicine.

Key Points: 
  • Unprecedented Cognitive Boost: MIRA1a demonstrated a doubling of the performance of normal adult mice in learning and memory tests, showcasing MIRA1a's potential to elevate cognitive abilities beyond normal thresholds.
  • "The revelation of MIRA1a's dramatic cognitive enhancement potential acutely after even a single dose marks a seismic shift in neuropsychiatric research," said Dr. Kaplin, MD, Ph.D., President and Chief Scientific Officer of MIRA.
  • "This discovery positions MIRA Pharmaceuticals at the forefront of transformative developments in psychotropic drug innovation."
  • Erez Aminov, Chief Executive Officer of MIRA, added: "At MIRA Pharmaceuticals, we are committed to seizing industry-defining opportunities.

MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

Retrieved on: 
Monday, November 20, 2023
Principal, Safety, Johns Hopkins, MIRA, DSM-IV codes, Hope, CSA, Chairperson, Controlled Substances Act, FDA, Depression, National Network, MD, Partnership, TRD, DEA, Doctor of Philosophy, Suicidal ideation, Mental health, Take-home naloxone program, MDSI, Schedule, Pharmaceutical industry, Ketamine, Esketamine

BALTIMORE, Nov. 20, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company, today announced a partnership with MIRALOGX, LLC, an intellectual property holding company established by MIRA's founder. Under an exclusive licensing agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments. This transformative collaboration includes a a $3 million line of credit extended by MIRALOGX to fund the initial development of Ketamir-2.

Key Points: 
  • Under an exclusive licensing agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments.
  • This transformative collaboration includes a a $3 million line of credit extended by MIRALOGX to fund the initial development of Ketamir-2.
  • Unlike Ketamine, which necessitates intravenous, intramuscular, or intranasal administration due to its limited oral bioavailability, in initial pre-clinical studies, Ketamir-2 appears to exhibit a more clinically desirable gastrointestinal absorption profile.
  • The combination of this exclusive licensing agreement and obtaining initial funding for development through the MIRALOGX line of credit propels MIRA into an exciting phase of innovation and development."

MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts

Retrieved on: 
Tuesday, September 5, 2023
Cognition, Learning, Communication, Partnership, MZ, CB2, CSO, Anxiety, Deficit spending, DSM-IV codes, Appetite, Doctor of Philosophy, Dementia, MD, Patient, Neuropathic pain, CB1, MIRA, Generalized anxiety disorder, THC, Memory, PTSD, Safety, Pharmaceutical industry

BALTIMORE, Sept. 5, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic THC analog, today announced its strategic partnership with MZ Group ("MZ"), a renowned international investor relations firm.

Key Points: 
  • BALTIMORE, Sept. 5, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic THC analog, today announced its strategic partnership with MZ Group ("MZ"), a renowned international investor relations firm.
  • As part of its commitment to effective communication with its stakeholders, MIRA has joined forces with MZ Group, leveraging their expertise and global presence.
  • MIRA aims to expand its presence in key markets through a comprehensive investor relations and financial communications program.
  • "Our collaboration with MZ Group underscores our commitment to becoming a leader in neurological markets and the expanding cannabis market," said Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals.